**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 52001

**Manuscript Type:**ORIGINAL ARTICLE

***Case Control Study***

**Nucleotide excision repair pathway gene polymorphisms are associated with risk and prognosis of colorectal cancer**

Li YK *et al*. NER pathway gene polymorphisms and CRC

Yan-Ke Li, Qian Xu, Li-Ping Sun, Yue-Hua Gong, Jing-Jing Jing, Cheng-Zhong Xing, Yuan Yuan

**Yan-Ke Li, Qian Xu, Li-Ping Sun, Yue-Hua Gong, Jing-Jing Jing, Cheng-Zhong Xing, Yuan Yuan,** Tumor Etiology and Screening Department of Cancer Institute and General Surgery, Key Laboratory of Cancer Etiology and Prevention of Liaoning Education Department, Key Laboratory of GI Cancer Etiology and Prevention of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China

**Yan-Ke Li**, **Cheng-Zhong Xing,** Department of Anorectal Surgery, the First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China

**Author contributions:** Yuan Y designed the study and revised the manuscript; Xing CZ recruited the patients; Sun LP collected the data; Xu Q, Gong YH, and Jing JJ performed the experiments; Li YK analyzed the data and drafted the manuscript.

**Supported by** the National Key R&D Program of China, No. 2018YFC1311600.

**Corresponding author: Yuan Yuan, MD, PhD, Professor,** Tumor Etiology and Screening Department of Cancer Institute and General Surgery, the First Hospital of China Medical University, No. 155, Nanjingbei Street, Heping District, Shenyang 110001, Liaoning Province, China. [yuanyuan@cmu.edu.cn](mailto:yuanyuan@cmu.edu.cn)

**Received:** October 12, 2019

**Revised:** December 26, 2019

**Accepted:** January 1, 2020

**Published online:**

**Abstract**

BACKGROUND

Single nucleotide polymorphisms (SNPs) are universally present in nucleotide excision repair (NER) pathway genes, which could make impacts on colorectal carcinogenesis and prognosis.

AIM

To explore the association of all tagSNPs in NER pathway genes with colorectal cancer (CRC) risk and prognosis in a northern Chinese population by a two-stage case-control design composed of a discovery and validation stage.

METHODS

Genotyping for NER SNPs was performed using kompetitive allele specific PCR. In the discovery stage, 39 tagSNPs in eight genes were genotyped in 368 subjects, including 184 CRC cases and 184 individual-matched controls. In the validation stage, 13 SNPs in six genes were analyzed in a total of 1712 subjects, including 854 CRC cases and 858 CRC-free controls.

RESULTS

Two SNPs (XPA rs10817938 and XPC rs2607775) were associated with an increased CRC risk in overall and stratification analyses. Significant cumulative and interaction effects were also demonstrated in the studied SNPs on CRC risk. Another two SNPs (ERCC2 rs1052555 and ERCC5 rs2228959) were newly found to be associated with a poor overall survival of CRC patients.

CONCLUSION

Our findings suggest novel SNPs in NER pathway genes that can be predictive for CRC risk and prognosis in a large-scale Chinese population. The present study has referential values for the identification of all-round NER-based genetic biomarkers in predicting the susceptibility and clinical outcome of CRC.

**Key words:** Nucleotide excision repair; Polymorphism; Colorectal cancer; Susceptibility; Prognosis

Li YK, Xu Q, Sun LP, Gong YH, Jing JJ, Xing CZ, Yuan Y. Nucleotide excision repair pathway gene polymorphisms are associated with risk and prognosis of colorectal cancer. *World J Gastroenterol* 2019; In press

**Core tip:** We conducted a two-stage case-control study to explore the association of all tag-single nucleotide polymorphisms (SNPs) in eight nucleotide excision repair pathway genes with colorectal cancer (CRC) risk and prognosis in a northern Chinese population, including a discovery and validation stage. We newly found that two SNPs (XPA rs10817938 and XPC rs2607775) contributed to an increased CRC risk in overall and stratification analyses. Another two SNPs (ERCC2 rs1052555 and ERCC5 rs2228959) were also first reported to be associated with a poor CRC prognosis.

**INTRODUCTION**

Colorectal cancer (CRC) is the third common malignant neoplasm and the fifth leading cause of cancer-related death in China. The incidence has been continuously rising in the past decades, which has exceeded the average levels both in developed and developing countries[1,2]. Genetic factors are thought to play a critical role in the susceptibility to CRC with hereditable factors estimated to account for 35% of the risk[3]. The identification of genetic biomarkers associated with CRC is quite crucial for its early diagnosis and treatment.

Nucleotide excision repair (NER) is one of the most versatile DNA repair pathways, which can protect cellular DNA against ultraviolet-induced cyclobutane pyrimidine dimers, DNA crosslinks, and bulky adducts[4]. It involves damage recognition, damage demarcation and unwinding, damage incision, and new strand ligation. All the stages are completed by eight key proteins, comprising DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, XPA, and XPC[5,6], which respond to a wide range of DNA damage but are particularly important for the removal of bulky adducts caused by environmental carcinogens, such as heterocyclic amines and polycyclic aromatic hydrocarbons. They are putative environmental risk factors for colorectal neoplasia, found in tobacco smoke and red meat cooked at high temperature[7,8]. Therefore, the dysfunction of NER system may interfere with DNA damage repair from these exogenous carcinogens, and contribute to CRC development.

Genetic variation of genes can lead to the dysfunction of their encoding proteins. As the most common genetic variants in human genomes, single nucleotide polymorphisms (SNPs) are universally present in NER pathway genes. It has been suggested that NER SNPs could influence the expression or function of corresponding proteins, leading to the aberration of DNA reparative process and thus making impacts on colorectal carcinogenesis and prognosis[9,10]. Accumulating studies have investigated the association of NER SNPs with CRC risk or prognosis in various regions. For instance, Paszkowska-Szczur *et al*[11] assessed the association between SNPs in seven XP genes (XPA-XPG) and CRC risk in the Polish population, and their results confirmed that polymorphisms in XPC (rs2228000) and XPD (rs1799793 and rs238406) might be associated with CRC risk. Another study reported by Dai *et al*[12] showed that the AA genotype of ERCC1 rs2336219 had a significantly increased CRC risk and the CC genotype of ERCC1 rs735482 was associated with a lower response to oxaliplatin-based chemotherapy, shorter survival, and higher risk of relapse or metastasis. Currently, however, most researches in this field are only focused on a few SNPs in partial NER genes. A comprehensive investigation for the association of NER pathway gene polymorphisms with CRC risk and prognosis based on a large-scale Chinese population remains lacking.

In the present study, we intend to explore the association of all tagSNPs in NER pathway genes with CRC risk and prognosis in a northern Chinese population by a two-stage case-control design composed of a discovery and validation stage. Our study aimed to identify all-round NER-based genetic biomarkers for prediction of the susceptibility to CRC and the clinical outcome of CRC patients, particularly applicable for China region.

**MATERIALS AND METHODS**

***Study subjects and study design***

The Ethics Committee of the First Hospital of China Medical University approved this project. All subjects provided written informed consent. A two-stage case-control study was designed. As an exploratory evaluation of selected candidate tagSNPs for disease risk, the first-stage study was carried out in a screening population of 184 CRC cases and 184 individual-matched controls (1:1) who were recruited between 2012 and 2014. Based on the initial results from these subjects, the secondary-stage study was subsequently performed in an enlarged population to validate the association of those SNPs who showed some hints in the discovery stage, consisting of 854 CRC cases and 858 frequency-matched controls in total. All the cases were selected from histopathologically confirmed CRC patients admitted to the Department of Anorectal Surgery of the First Hospital of China Medical University between September 2012 and March 2018. The controls were recruited from the healthy subjects seeking for physical examination at the hospital and the inpatients diagnosed with benign anal diseases by digital rectal examination or other approaches during the same period. The control group was matched to the case group based on gender and age (± 5 years). Fasting venous blood sample (5 mL) was collected from each participant.

***Information collection***

The epidemiological information of study participants was collected by a questionnaire survey or from the medical records of inpatients, including smoking history, drinking history, and *Helicobacter pylori* (*H. pylori)* infection status. The clinicopathological data were obtained from the pathological reports of surgical patients. Clinical staging for CRC was performed according to the UICC/AJCC TNM staging system (2002). Regular follow-up was conducted for CRC patients after radical surgery until October 2018. A total of 565 cases with available survival information were involved in the prognosis study, including survival status and overall survival (OS).

***SNP screening***

A two-step strategy was adopted for SNP selection in this association study. First, we extracted all the eight NER pathway genes encompassing 5 kb of upstream and downstream flanking sequences from the HapMap Chinese Han Beijing population (http://www.HapMap.org)[6]. Then, the genome sequences were imported into Haploview 4.2 software to select all the tagSNPs in NER pathway genes according to the following criteria: (1) Minor allele frequency (MAF) in CHB > 0.05; and (2) linkage disequilibrium (LD) *r*2 < 0.8. Consequently, a total of 39 candidate tagSNPs were enrolled in the discovery stage. Second, we evaluated the association between all of them and CRC risk in a small sample size. And SNP function prediction was performed using SNPinfo Web Server (https://snpinfo.niehs.nih.gov). Based on the analyses from the two aspects, we further screened out several SNPs for the next large-scale exploration. The screening principles were set as follows: (1) Showing a significant or borderline association with CRC risk; or (2) having potential biological function; and (3) having two alleles that suited for batch genotyping. Finally, 13 SNPs in six NER pathway genes were selected as research targets in the validation stage, including DDB2 rs2029298; ERCC1 rs11615 and rs735482; ERCC2 rs1052555 and rs50871; ERCC5 rs1047768, rs2094258, rs2228959, rs2296147, and rs873601; XPA rs10817938 and rs3176629; and XPC rs2607775.

***SNP genotyping***

Genomic DNA was isolated from each blood sample using the phenol-chloroform method. Genotyping was conducted using kompetitive allele specific PCR with the SNPLine platform (LGC Genomics, Hoddesdon, United Kingdom) by Shanghai Baygene Biotechnology Company Limited (China)[13]. Additionally, 10% of samples were randomly chosen to be repeatedly assayed for quality control, and the results of duplicated samples reached a 100% consistency.

***Statistical analysis***

*χ*2 test was used to calculate the Hardy-Weinberg equilibrium (HWE) for studied SNPs in the control group and evaluate the differences in the baseline characteristics between case and control groups. The association of each SNP with CRC risk was estimated using multiple logistic regression by calculating odds ratio (OR) and 95% confidence interval (95%CI) adjusted by gender and age. Linear regression was applied to assess the cumulative effect of increasing SNP genotypes associated with CRC risk. Haplotype analysis was performed employing SHEsis online software (http://analysis.bio-x.cn/myAnalysis.php). Log likelihood ratio test was used to evaluate the interaction between each SNP and environmental factors on CRC risk. Kaplan-Meier method was applied to figure out median survival time (MST) and mean survival time was adopted when MST could not be calculated. Log rank test was used to judge the differences in the survival distribution between groups. The association of each SNP with CRC prognosis was estimated using Cox regression both in univariate and multivariate modes by calculating hazard ratio with 95%CI. The dominant and recessive genetic models were, respectively, defined as variant homozygote + heterozygote *vs* wild homozygote and variant homozygote *vs* heterozygote + wild homozygote. All statistical analyses mentioned above were performed with SPSS 22.0 software (Chicago, IL, United States). All the *P*-values were two-sided and statistical significance was regarded at *P* < 0.05, except the risk study in the discovery stage (*P* < 0.1).

**RESULTS**

***Characteristics of study participants***

In the discovery stage, 39 tagSNPs in eight NER pathway genes were genotyped in 368 subjects. The case and control groups were exactly matched (Table S1). In the validation stage, 13 SNPs in six genes were analyzed in a total of 1712 subjects, including 854 CRC cases and 858 CRC-free controls, which were also successfully matched by gender and age. Notably, the *H. pylori* infection rate was significantly higher in CRC patients than in the controls (*P* < 0.001). No significant difference was shown in the distribution of individuals with smoking or drinking history between the two groups (Table S2).

***Basic information and function prediction results of NER SNPs***

The basic information and function prediction results of all tagSNPs in NER pathway genes are presented in Table 1. The assessment items for SNP function mainly contained non-synonymous SNP (nsSNP), splicing site, splicing abolish domain, exon splicing enhancer (ESE) or exon splicing silencer (ESS), stop codon, Polyphen, and transcription factor binding site.

***Association of NER SNPs with CRC risk***

In the discovery stage, the association between all tagSNPs in NER pathway genes and CRC risk was initially investigated. The results showed that seven SNPs were associated with CRC risk in a screening population (*P* < 0.1, Table S3). Combined with the findings in SNP function prediction, 13 NER SNPs were chosen in the next association study with an enlarged population.

In the validation stage, we first evaluated the association between each SNP and CRC risk in overall subjects. The genotype frequency of three SNPs in the control group did not meet the HWE (*P*HWE < 0.05), including ERCC2 rs50871, ERCC5 rs2228959, and XPA rs3176629. On this account, they were excluded from subsequent risk study. The validated results showed that two NER SNPs were found to be associated with CRC risk. The XPA rs10817938 polymorphism conferred to an increased CRC risk in its variant homozygote and recessive model (CC *vs* TT: *P* = 0.021, OR = 1.70, 95%CI = 1.08-2.66; CC *vs* TC + TT: *P* = 0.033, OR = 1.62, 95%CI = 1.04-2.52). The variant genotypes of XPC rs2607775 polymorphism could also enhance disease risk when compared with the wild type (CG *vs* CC: *P* = 0.027, OR = 1.49, 95%CI = 1.05-2.13; CG + GG *vs* CC: *P* = 0.016, OR = 1.54, 95%CI = 1.09-2.18, Table 2).

A stratification analysis was further performed based on host characteristics, including gender and age. The associations of XPA rs10817938 and XPC rs2607775 polymorphisms with CRC risk were both demonstrated in the subgroups of male and age ≤ 60 years, while no hint was shown in the opposite groups. All related variant genotypes of them were linked to an increased CRC risk in the specific subgroups. Similar to the overall analysis, no association was observed in other NER SNPs with CRC risk either (Table S4).

***Cumulative effect of risk-related NER SNPs***

Based on the findings shown in the last part, we explored the cumulative effect of NER SNPs on CRC risk. The best genetic models were identified for each polymorphism: XPA rs10817938 CC *vs* TC + TT and XPC rs2607775 CG + GG *vs* CC. According to the number of risk genotypes that individuals carried with, all the subjects were categorized into three groups (0, 1, and 2). Then, we analyzed the linear trend in CRC risk. The disease risk was found to be significantly enhanced with the increasing number of risk genotypes of studied SNPs (*P*trend = 0.001, Table 3).

***Association of NER SNP haplotypes with CRC risk***

A haplotype analysis was conducted for the SNPs in the same NER pathway gene, including ERCC1 rs11615-rs735482 and ERCC5 rs1047768-rs2094258-rs2296147-rs873601. The association between each haplotype and CRC risk was evaluated. It was suggested that one haplotype of ERCC5, C-G-C-G, demonstrated borderline significance in the association with CRC risk (*P* = 0.051, OR = 1.47, 95%CI = 1.00-2.17, Table S5).

***Interaction of NER SNPs with environmental factors***

We further investigated the interaction effects of NER SNPs with environmental factors on CRC risk, including smoking, drinking, and *H. pylori* infection. The DDB2 rs2029298 polymorphism could be negatively interacted with drinking. Its GG genotype could reduce CRC risk by 0.52-fold in the population with drinking history when compared with GA + AA genotype (*P*interaction = 0.019, OR = 0.52, 95%CI = 0.30-0.90). No interaction was shown between NER SNPs and smoking or *H. pylori* infection (Table 4).

***Association of NER SNPs with CRC prognosis***

Before the prognosis study, an assessment was made at first for the association between host factors and the OS of CRC patients, including all the epidemiological and clinicopathological characteristics. We found the OS could be affected by TNM stage, macroscopic type, histological type, depth of invasion, growth mode, and lymphatic metastasis (*P* < 0.001). Therefore, these factors were treated as adjustment parameters in the subsequent multivariate survival analysis (Table 5).

The association between NER SNPs and CRC prognosis was evaluated next. Two SNPs showed a significant association with prognosis in both univariate and multivariate analyses. The variant homozygote of ERCC2 rs1052555 polymorphism suggested a worse OS in CRC patients (TT *vs* CC: *P* = 0.010, OR = 14.99, 95%CI = 1.90-118.10; TT *vs* CT + CC: *P* = 0.009, OR = 15.89, 95%CI = 2.20-125.16). A similar trend was also indicated in the ERCC5 rs2228959 polymorphism, which conferred to a poor CRC prognosis as well (AA *vs* CC: *P* = 0.046, OR = 4.32, 95%CI = 1.03-18.17; AA *vs* CA + CC: *P* = 0.049, OR = 4.20, 95%CI = 1.00-17.60, Table 6).

**DISCUSSION**

In the present study, we explored the association of all tagSNPs in eight NER pathway genes with CRC risk and prognosis in a total of 1712 northern Chinese. In the discovery stage, 39 tagSNPs were analyzed for their association and potential biological function, and 13 SNPs were enrolled in the validation stage. Among them, the XPA rs10817938 and XPC rs2607775 polymorphisms were found to be associated with CRC risk both in overall and stratified analyses. They also demonstrated cumulative effects on disease risk with the increasing number of risk genotypes. Moreover, the DDB2 rs2029298 polymorphism had a negative interaction effect with drinking on CRC risk. In the prognosis study, the ERCC2 rs1052555 and ERCC5 rs2228959 polymorphisms were associated with the OS of CRC cases. To our knowledge, this is the first comprehensive report on the association of NER SNPs with CRC risk and prognosis based on a large-scale Chinese population.

In our research, the XPA rs10817938 and XPC rs2607775 polymorphisms showed a significant association with an increased CRC risk. The XPA (xeroderma pigmentosum group A) gene, located in chromosome 9q22.3 containing 9 exons and 8 introns, encodes a zinc finger DNA-binding protein involved in NER to maintain genomic integrity[14]. It was suggested that the XPA protein was significantly decreased in CRC tissue than in adjacent non-tumor tissue, and its high expression showed an association with better survival of CRC cases[15]. Therefore, XPA is a CRC-related protein marker. The gene polymorphisms in XPA were also revealed to be associated with CRC risk, such as 23Gly/Ala (rs1800975)[16-19]. However, rare studies have focused on the rs10817938 polymorphism, which has been only reported by Hu *et al*[20] that rs10817938 CT/TT genotype retains a significant association with a longer OS (*P* = 0.008) in CRC patients receiving oxaliplatin-based chemotherapy. Thus, our study first referred to it as a CRC risk-related SNP. Similar to XPA, the XPC (xeroderma pigmentosum group C) gene is also a well-accepted marker related to CRC, which is located in chromosome 3p25 with 16 exons and 15 introns[21]. It encodes a 940-amino acid protein involved in DNA damage recognition and DNA repair initiation in the NER pathway, and the binding of XPC to damaged DNA is the rate-limiting step for NER[22-24]. The XPC gene is highly polymorphic and its SNPs have been foci of interest for the association with CRC risk, such as 939Lys/Gln (rs2228001) and 499Ala/Val (rs2228000)[25-29]. In our study, we newly found that the rs2607775 polymorphism could modulate CRC risk. In a word, the XPA rs10817938 and XPC rs2607775 polymorphisms could be potential genetic markers applicable for the prediction of CRC susceptibility in the future.

In the stratified analysis, it is noteworthy that the two meaningful SNPs for CRC risk in the overall population only demonstrated their association in the male and age ≤ 60 years subgroups, while no significance was found in the female and age > 60 years subgroups. The risk effects of NER SNPs seemed to change with gender and age. The morbidity and mortality of CRC are higher in men than in women both in China and worldwide[1,30]. That could be attributed to a subset of X-chromosome genes escaping X-inactivation, named “escape from X-inactivation tumor-suppressor” (EXITS) genes, which would protect females from complete functional loss by a single mutation and thus result in sex bias in a variety of tumor types[31]. In addition, it is well acknowledged that CRC incidence strongly increases with age, probably due to the weakened immunity and accumulated carcinogens with people aging[30,32]. As a result, the association of NER SNPs could be masked by gender and age but manifested when the two factors are considered as stratification items to eliminate their effects on CRC risk. These findings suggested the XPA rs10817938 and XPC rs2607775 polymorphisms might also be predictive biomarkers for the susceptibility to CRC in some specific populations like males or youngsters.

Owing to the multiple elements involved in carcinogenesis, the efficacy of single polymorphism for risk detection is relatively limited. And the combination of multi-variants usually has more advantages[33,34]. In our study, a significant cumulative trend was shown in NER SNPs for the association with CRC risk, which could be enhanced with the increasing number of risk genotypes (XPA rs10817938 CC and XPC rs2607775 CG + GG). That indicated a dosage effect of risk-related NER SNPs that an individual carried with. Moreover, borderline significance linked to CRC risk was observed in a haplotype of ERCC5 rs1047768-rs2094258-rs2296147-rs873601 (C-G-C-G). Therefore, better diagnostic capacity for the susceptibility to CRC could be obtained when combining multiple SNPs in NER pathway genes.

Except for genetic factors, environmental factors also play a vital role in CRC development such as tobacco smoking, alcohol consumption, and dietary constituents especially red meat[35-37]. Knowledge of gene-environment interactions may help to elucidate substantial hidden heritability within the architecture of cancer initiation[38]. The effects of interaction between SNPs in NER pathway genes and environmental factors on CRC risk has been preliminarily explored[39]. Here, we newly found that the DDB2 rs2029298 polymorphism could be negatively interacted with drinking-related CRC risk. In contrast to this, no association was found in any DDB2 SNP in the main effect analysis. Alcohol consumption is a well-recognized carcinogen of CRC due to DNA lesion caused by the exposure of DNA to acetaldehyde produced by ethanol[40]. However, the effect of DDB2 rs2029298 polymorphism was modified in the population with drinking history and its GG genotype decreased CRC risk by 0.52-fold, suggesting that an antagonism existed between DDB2 SNPs with drinking. Hence, the interactions between NER SNPs and environmental factors may also benefit the risk prediction of CRC. The possible mechanism concerned with our findings needs to be clarified by further researches.

In addition to CRC susceptibility, the influence of SNPs in NER pathway genes on CRC prognosis cannot be ignored either. The present study showed that the ERCC2 rs1052555 and ERCC5 rs2228959 polymorphisms were associated with a poor OS in CRC patients. The ERCC2 (excision repair cross-complementing group 2) gene, also known as XPD (xeroderma pigmentosum group D) with 24 exons and 23 introns, encodes a helicase, which is a component of transcription factor TFIIH participating in the opening of damaged DNA during NER[41]. Mounting evidence has demonstrated that the SNPs in ERCC2 have predictive values for the clinical outcome of CRC patients treated with various chemotherapy, such as 751Lys/Gln (13181)[42-46]. However, no report has referred to the rs1052555 polymorphism yet, which is located in exon 24 of ERCC2. According to the SNP function prediction, it may affect the splicing pattern of mRNA after transcription as a result of the formation of splicing abolish domain or ESE/ESS. And both the RegPotential and Conservation scores were relatively high, suggesting that it might be a highly conserved variant in the course of evolution with regulatory roles. Therefore, the ERCC2 rs1052555 polymorphism is very likely to be a functional SNP and should be paid more attention in the future. The other highly polymorphic NER gene, ERCC5 (excision repair cross-complementing group 5) or XPG (xeroderma pigmentosum group G), is located in chromosome 13q22-123, consisting of 15 exons and 14 introns[47]. The protein of 1186 amino acids encoded by ERCC5 is a member of the flap structure-specific endonuclease (FEN1) family and plays an essential role in the two incision steps of NER[48,49]. A few SNPs in ERCC5 have been reported to be associated with CRC prognosis although the rs2228959 polymorphism is not covered, which belongs to exon 8 of the gene[50-53]. Interestingly, the SNP function prediction showed no special hint for its potential biological function. A reasonable interpretation for the phenomenon could be that the observation on CRC prognosis might not result from the focused polymorphism rs2228959, instead, another undiscovered variant in strong LD with it located in ERCC5 or neighbor genes[54]. Anyway, the ERCC2 rs1052555 and ERCC5 rs2228959 polymorphisms could be novel genetic biomarkers with predictive values for the clinical outcome of CRC patients. Further investigations are needed to validate all the assumptions.

Some limitations in our study should be acknowledged. First, the design of a retrospective case-control study had its inherent limitations. Second, a small percentage of data missing may influence the statistical efficacy to some extent. Additionally, only association study was emphasized in our research. All involved mechanisms need to be investigated by in-depth molecular experiments in the future.

In summary, a two-stage case-control study was performed to explore the association of all tagSNPs in eight NER pathway genes with CRC risk and prognosis in a northern Chinese population, including a discovery and validation stage. Two SNPs (XPA rs10817938 and XPC rs2607775) were found to contribute to an increased CRC risk in overall and stratification analyses. Another two SNPs (ERCC2 rs1052555 and ERCC5 rs2228959) were found to be associated with a poor CRC prognosis. The present study has referential values for the identification of NER-based genetic biomarkers in predicting the susceptibility and clinical outcome of CRC, and may also provide clues for the access to individualized early diagnosis and therapy of CRC patients.

**ARTICLE HIGHLIGHTS**

***Research background***

Single nucleotide polymorphisms (SNPs) are universally present in nucleotide excision repair (NER) pathway genes. Previous studies have suggested that NER SNPs could make impacts on colorectal cancer (CRC) risk and prognosis.

***Research motivation***

Currently, most researches in this field are only focused on a few SNPs in partial NER genes. A comprehensive investigation based on a large-scale Chinese population remains lacking.

***Research objectives***

The study aimed to explore the association of all tagSNPs in NER pathway genes with CRC risk and prognosis in a northern Chinese population by a two-stage case-control design composed of a discovery and validation stage.

***Research methods***

Genotyping for NER SNPs was performed using kompetitive allele specific PCR. In the discovery stage, 39 tagSNPs in eight genes were genotyped in 368 subjects, including 184 CRC cases and 184 individual-matched controls. In the validation stage, 13 SNPs in six genes were analyzed in a total of 1712 subjects, including 854 CRC cases and 858 CRC-free controls.

***Research results***

We found that two SNPs (XPA rs10817938 and XPC rs2607775) were associated with an increased CRC risk in overall and stratification analyses. Significant cumulative and interaction effects were also demonstrated in the studied SNPs on CRC risk. Another two SNPs (ERCC2 rs1052555 and ERCC5 rs2228959) were newly found to be associated with a poor overall survival in CRC patients.

***Research conclusions***

Our findings suggested novel predictive SNPs in NER pathway genes for CRC risk and prognosis in a large-scale Chinese population.

***Research perspectives***

The present study has referential values for the identification of NER-based genetic biomarkers in predicting the susceptibility and clinical outcome of CRC, and may also provide clues for the access to individualized early diagnosis and therapy of CRC patients.

**REFERENCES**

1 **Fang JY**, Dong HL, Sang XJ, Xie B, Wu KS, Du PL, Xu ZX, Jia XY, Lin K. Colorectal Cancer Mortality Characteristics and Predictions in China, 1991-2011. *Asian Pac J Cancer Prev* 2015; **16**: 7991-7995 [PMID: 26625831 DOI: 10.7314/apjcp.2015.16.17.7991]

2 **Zhang L**, Cao F, Zhang G, Shi L, Chen S, Zhang Z, Zhi W, Ma T. Trends in and Predictions of Colorectal Cancer Incidence and Mortality in China From 1990 to 2025. *Front Oncol* 2019; **9**: 98 [PMID: 30847304 DOI: 10.3389/fonc.2019.00098]

3 **Lichtenstein P**, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med* 2000; **343**: 78-85 [PMID: 10891514 DOI: 10.1056/NEJM200007133430201]

4 **Petruseva IO**, Evdokimov AN, Lavrik OI. Molecular mechanism of global genome nucleotide excision repair. *Acta Naturae* 2014; **6**: 23-34 [PMID: 24772324]

5 **Nouspikel T**. DNA repair in mammalian cells: Nucleotide excision repair: variations on versatility. *Cell Mol Life Sci* 2009; **66**: 994-1009 [PMID: 19153657 DOI: 10.1007/s00018-009-8737-y]

6 **Liu J**, Sun L, Xu Q, Tu H, He C, Xing C, Yuan Y. Association of nucleotide excision repair pathway gene polymorphisms with gastric cancer and atrophic gastritis risks. *Oncotarget* 2016; **7**: 6972-6983 [PMID: 26760766 DOI: 10.18632/oncotarget.6853]

7 **Giovannucci E**. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 2001; **10**: 725-731 [PMID: 11440957]

8 **Sandhu MS**, White IR, McPherson K. Systematic review of the prospective cohort studies on meat consumption and colorectal cancer risk: a meta-analytical approach. *Cancer Epidemiol Biomarkers Prev* 2001; **10**: 439-446 [PMID: 11352852]

9 **Berndt SI**, Platz EA, Fallin MD, Thuita LW, Hoffman SC, Helzlsouer KJ. Genetic variation in the nucleotide excision repair pathway and colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev* 2006; **15**: 2263-2269 [PMID: 17119055 DOI: 10.1158/1055-9965.EPI-06-0449]

10 **Moreno V**, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I, González S, Guino E, Capellà G, Canzian F. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. *Clin Cancer Res* 2006; **12**: 2101-2108 [PMID: 16609022 DOI: 10.1158/1078-0432.CCR-05-1363]

11 **Paszkowska-Szczur K**, Scott RJ, Górski B, Cybulski C, Kurzawski G, Dymerska D, Gupta S, van de Wetering T, Masojć B, Kashyap A, Gapska P, Gromowski T, Kładny J, Lubiński J, Dębniak T. Polymorphisms in nucleotide excision repair genes and susceptibility to colorectal cancer in the Polish population. *Mol Biol Rep* 2015; **42**: 755-764 [PMID: 25391773 DOI: 10.1007/s11033-014-3824-z]

12 **Dai Q**, Luo H, Li XP, Huang J, Zhou TJ, Yang ZH. XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population. *Mutagenesis* 2015; **30**: 441-449 [PMID: 25690281 DOI: 10.1093/mutage/geu088]

13 **Lv Z**, Xu Q, Sun L, Wen J, Fang X, Xing C, Yuan Y. Four novel polymorphisms in long non-coding RNA HOTTIP are associated with the risk and prognosis of colorectal cancer. *Biosci Rep* 2019; **39**: [PMID: 30940774 DOI: 10.1042/BSR20180573]

14 **Asahina H**, Kuraoka I, Shirakawa M, Morita EH, Miura N, Miyamoto I, Ohtsuka E, Okada Y, Tanaka K. The XPA protein is a zinc metalloprotein with an ability to recognize various kinds of DNA damage. *Mutat Res* 1994; **315**: 229-237 [PMID: 7526200 DOI: 10.1016/0921-8777(94)90034-5]

15 **Feng X**, Liu J, Gong Y, Gou K, Yang H, Yuan Y, Xing C. DNA repair protein XPA is differentially expressed in colorectal cancer and predicts better prognosis. *Cancer Med* 2018; **7**: 2339-2349 [PMID: 29675892 DOI: 10.1002/cam4.1480]

16 **Liu J**, Zhang Z, Cao XL, Lei DP, Wang ZQ, Jin T, Pan XL. XPA A23G polymorphism and susceptibility to cancer: a meta-analysis. *Mol Biol Rep* 2012; **39**: 6791-6799 [PMID: 22314912 DOI: 10.1007/s11033-012-1504-4]

17 **Dziki L**, Dziki A, Mik M, Majsterek I, Kabzinski J. Modulation of Colorectal Cancer Risk by Polymorphisms in 51Gln/His, 64Ile/Val, and 148Asp/Glu of APEX Gene; 23Gly/Ala of XPA Gene; and 689Ser/Arg of ERCC4 Gene. *Gastroenterol Res Pract* 2017; **2017**: 3840243 [PMID: 28386271 DOI: 10.1155/2017/3840243]

18 **He L**, Deng T, Luo H. XPA A23G polymorphism and risk of digestive system cancers: a meta-analysis. *Onco Targets Ther* 2015; **8**: 385-394 [PMID: 25709470 DOI: 10.2147/OTT.S75767]

19 **Monzo M**, Moreno I, Navarro A, Ibeas R, Artells R, Gel B, Martinez F, Moreno J, Hernandez R, Navarro-Vigo M. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine. *Oncology* 2007; **72**: 364-370 [PMID: 18204222 DOI: 10.1159/000113534]

20 **Hu X**, Qin W, Li S, He M, Wang Y, Guan S, Zhao H, Yao W, Wei M, Liu M, Wu H. Polymorphisms in DNA repair pathway genes and *ABCG2* gene in advanced colorectal cancer: correlation with tumor characteristics and clinical outcome in oxaliplatin-based chemotherapy. *Cancer Manag Res* 2019; **11**: 285-297 [PMID: 30643454 DOI: 10.2147/CMAR.S181922]

21 **Li L**, Peterson C, Legerski R. Sequence of the mouse XPC cDNA and genomic structure of the human XPC gene. *Nucleic Acids Res* 1996; **24**: 1026-1028 [PMID: 8604333 DOI: 10.1093/nar/24.6.1026]

22 **Leibeling D**, Laspe P, Emmert S. Nucleotide excision repair and cancer. *J Mol Histol* 2006; **37**: 225-238 [PMID: 16855787 DOI: 10.1007/s10735-006-9041-x]

23 **Tapias A**, Auriol J, Forget D, Enzlin JH, Schärer OD, Coin F, Coulombe B, Egly JM. Ordered conformational changes in damaged DNA induced by nucleotide excision repair factors. *J Biol Chem* 2004; **279**: 19074-19083 [PMID: 14981083 DOI: 10.1074/jbc.M312611200]

24 **Thoma BS**, Vasquez KM. Critical DNA damage recognition functions of XPC-hHR23B and XPA-RPA in nucleotide excision repair. *Mol Carcinog* 2003; **38**: 1-13 [PMID: 12949838 DOI: 10.1002/mc.10143]

25 **Ahmad Aizat AA**, Siti Nurfatimah MS, Aminudin MM, Ankathil R. XPC Lys939Gln polymorphism, smoking and risk of sporadic colorectal cancer among Malaysians. *World J Gastroenterol* 2013; **19**: 3623-3628 [PMID: 23801864 DOI: 10.3748/wjg.v19.i23.3623]

26 **Mucha B**, Pytel D, Markiewicz L, Cuchra M, Szymczak I, Przybylowska-Sygut K, Dziki A, Majsterek I, Dziki L. Nucleotide Excision Repair Capacity and XPC and XPD Gene Polymorphism Modulate Colorectal Cancer Risk. *Clin Colorectal Cancer* 2018; **17**: e435-e441 [PMID: 29793654 DOI: 10.1016/j.clcc.2016.10.001]

27 **Steck SE**, Butler LM, Keku T, Antwi S, Galanko J, Sandler RS, Hu JJ. Nucleotide excision repair gene polymorphisms, meat intake and colon cancer risk. *Mutat Res* 2014; **762**: 24-31 [PMID: 24607854 DOI: 10.1016/j.mrfmmm.2014.02.004]

28 **Hua RX**, Zhu J, Jiang DH, Zhang SD, Zhang JB, Xue WQ, Li XZ, Zhang PF, He J, Jia WH. Association of XPC Gene Polymorphisms with Colorectal Cancer Risk in a Southern Chinese Population: A Case-Control Study and Meta-Analysis. *Genes (Basel)* 2016; **7**: 73 [PMID: 27669310 DOI: 10.3390/genes7100073]

29 **Peng Q**, Lao X, Tang W, Chen Z, Li R, Qin X, Li S. XPC Lys939Gln polymorphism contributes to colorectal cancer susceptibility: evidence from a meta-analysis. *Diagn Pathol* 2014; **9**: 120 [PMID: 24947936 DOI: 10.1186/1746-1596-9-120]

30 **Brenner H**, Kloor M, Pox CP. Colorectal cancer. *Lancet* 2014; **383**: 1490-1502 [PMID: 24225001 DOI: 10.1016/S0140-6736(13)61649-9]

31 **Dunford A**, Weinstock DM, Savova V, Schumacher SE, Cleary JP, Yoda A, Sullivan TJ, Hess JM, Gimelbrant AA, Beroukhim R, Lawrence MS, Getz G, Lane AA. Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. *Nat Genet* 2017; **49**: 10-16 [PMID: 27869828 DOI: 10.1038/ng.3726]

32 **Torre LA**, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015; **65**: 87-108 [PMID: 25651787 DOI: 10.3322/caac.21262]

33 **Hu X**, Yuan P, Yan J, Feng F, Li X, Liu W, Yang Y. Gene Polymorphisms of ADIPOQ +45T>G, UCP2 -866G>A, and FABP2 Ala54Thr on the Risk of Colorectal Cancer: A Matched Case-Control Study. *PLoS One* 2013; **8**: e67275 [PMID: 23826253 DOI: 10.1371/journal.pone.0067275]

34 **Li X**, Liu W, Feng F, Hu X, Yuan P, Yan J, Yang Y. [Association between adiponectin rs2241766, rs1501299 polymorphisms and the risk of colorectal cancer]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2014; **35**: 195-199 [PMID: 24739564]

35 **Hecht SS**, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. *Carcinogenesis* 1988; **9**: 875-884 [PMID: 3286030 DOI: 10.1093/carcin/9.6.875]

36 **Sinha R**, Peters U, Cross AJ, Kulldorff M, Weissfeld JL, Pinsky PF, Rothman N, Hayes RB. Meat, meat cooking methods and preservation, and risk for colorectal adenoma. *Cancer Res* 2005; **65**: 8034-8041 [PMID: 16140978 DOI: 10.1158/0008-5472.CAN-04-3429]

37 **Fang JL**, Vaca CE. Detection of DNA adducts of acetaldehyde in peripheral white blood cells of alcohol abusers. *Carcinogenesis* 1997; **18**: 627-632 [PMID: 9111191 DOI: 10.1093/carcin/18.4.627]

38 **Lv Z**, Sun L, Xu Q, Gong Y, Jing J, Dong N, Xing C, Yuan Y. SNP interactions of PGC with its neighbor lncRNAs enhance the susceptibility to gastric cancer/atrophic gastritis and influence the expression of involved molecules. *Cancer Med* 2018; **7**: 5252-5271 [PMID: 30155999 DOI: 10.1002/cam4.1743]

39 **Hansen RD**, Sørensen M, Tjønneland A, Overvad K, Wallin H, Raaschou-Nielsen O, Vogel U. XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancer. *Mutat Res* 2007; **619**: 68-80 [PMID: 17363013 DOI: 10.1016/j.mrfmmm.2007.02.002]

40 **Brooks PJ**, Theruvathu JA. DNA adducts from acetaldehyde: implications for alcohol-related carcinogenesis. *Alcohol* 2005; **35**: 187-193 [PMID: 16054980 DOI: 10.1016/j.alcohol.2005.03.009]

41 **Fuss JO**, Tainer JA. XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase. *DNA Repair (Amst)* 2011; **10**: 697-713 [PMID: 21571596 DOI: 10.1016/j.dnarep.2011.04.028]

42 **Kjersem JB**, Thomsen M, Guren T, Hamfjord J, Carlsson G, Gustavsson B, Ikdahl T, Indrebø G, Pfeiffer P, Lingjærde O, Tveit KM, Wettergren Y, Kure EH. AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin. *Pharmacogenomics J* 2016; **16**: 272-279 [PMID: 26261061 DOI: 10.1038/tpj.2015.54]

43 **Kumamoto K**, Ishibashi K, Okada N, Tajima Y, Kuwabara K, Kumagai Y, Baba H, Haga N, Ishida H. Polymorphisms of *GSTP1*, *ERCC2* and *TS*-3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. *Oncol Lett* 2013; **6**: 648-654 [PMID: 24137384 DOI: 10.3892/ol.2013.1467]

44 **Chen YM**, Wu XL, Zhang LW, Xu X, Liu JW. [Relationship between single nucleotide polymorphism in repair gene XPD751 and prognosis in colorectal carcinoma patients]. *Zhonghua Zhong Liu Za Zhi* 2012; **34**: 501-505 [PMID: 22967467 DOI: 10.3760/cma.j.issn.0253-3766.2012.07.006]

45 **Dong Y**, Liu JW, Gao YJ, Zhou T, Chen YM. Relationship between DNA repair gene XPD751 single-nucleotide polymorphisms and prognosis of colorectal cancer. *Genet Mol Res* 2015; **14**: 5390-5398 [PMID: 26125734 DOI: 10.4238/2015.May.22.8]

46 **Gan Y**, Li XR, Chen DJ, Wu JH. Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a Chinese population. *Asian Pac J Cancer Prev* 2012; **13**: 5721-5724 [PMID: 23317245 DOI: 10.7314/apjcp.2012.13.11.5721]

47 **Emmert S**, Schneider TD, Khan SG, Kraemer KH. The human XPG gene: gene architecture, alternative splicing and single nucleotide polymorphisms. *Nucleic Acids Res* 2001; **29**: 1443-1452 [PMID: 11266544 DOI: 10.1093/nar/29.7.1443]

48 **Kiyohara C**, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. *Int J Med Sci* 2007; **4**: 59-71 [PMID: 17299578 DOI: 10.7150/ijms.4.59]

49 **Wood RD**, Mitchell M, Lindahl T. Human DNA repair genes, 2005. *Mutat Res* 2005; **577**: 275-283 [PMID: 15922366 DOI: 10.1016/j.mrfmmm.2005.03.007]

50 **Chen J**, Luo X, Xie G, Chen K, Jiang H, Pan F, Li J, Ruan Z, Pang X, Liang H. Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy. *Medicine (Baltimore)* 2016; **95**: e3652 [PMID: 27175691 DOI: 10.1097/MD.0000000000003652]

51 **Kong J**, Liu Z, Cai F, Xu X, LiuI J. Relationship between the Asp1104His polymorphism of the nucleotide excision repair gene ERCC5 and treatment sensitivity to oxaliplatin in patients with advanced colorectal cancer in China. *Clinics (Sao Paulo)* 2018; **73**: e455 [PMID: 30517302 DOI: 10.6061/clinics/2017/e455]

52 **Sun K**, Gong A, Liang P. Predictive impact of genetic polymorphisms in DNA repair genes on susceptibility and therapeutic outcomes to colorectal cancer patients. *Tumour Biol* 2015; **36**: 1549-1559 [PMID: 25355595 DOI: 10.1007/s13277-014-2721-3]

53 **Wang F**, Zhang SD, Xu HM, Zhu JH, Hua RX, Xue WQ, Li XZ, Wang TM, He J, Jia WH. XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer. *Oncotarget* 2016; **7**: 11724-11732 [PMID: 26887052 DOI: 10.18632/oncotarget.7352]

54 **Li Y**, Zhang F, Yang D. Comprehensive assessment and meta-analysis of the association between CTNNB1 polymorphisms and cancer risk. *Biosci Rep* 2017; **37**: [PMID: 28963373 DOI: 10.1042/BSR20171121]

**Footnotes**

**Institutional review board statement:** The study was approved by the Ethics Committee of the First Hospital of China Medical University.

**Informed consent statement:** All subjects provided written informed consent.

**Conflict-of-interest statement:** The authors declare no conflict of interest.

**Data sharing statement:** No additional data is available.

**STROBE statement:** The guidelines of STROBE Statement have been adopted.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** October 12, 2019

**First decision:** November 27, 2019

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Sazci A, Yong D **S-Editor:** Wang J **L-Editor:** Wang TQ **E-Editor:**

**Table 1 Function prediction of nucleotide excision repair polymorphisms in the discovery stage**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **SNP** | **Chromosome** | **Nearby gene** | **Allele** | **Position** | **nsSNP** | **Splicing (site)** | **Splicing (abolish domain)** | **Splicing (ESE or ESS)** | **Stop Codon** | **Polyphen** | **SNPs3D (svm profile)** | **SNPs3D (svm structure)** | **TFBS** | **miRNA (miRanda)** | **miRNA (Sanger)** | **RegPotential** | **Conservation** |
|
| rs2029298 | 11 | *DDB2* | A/G | Promoter | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | 0 | 0.001 |
| rs326222 | 11 | *DDB2* | C/T | Intron | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0.001 |
| rs3781619 | 11 | *DDB2* | A/G | Intron | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | NA | 0 |
| rs830083 | 11 | *DDB2* | A/C/G/T | Intron | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | NA | 0 |
| rs11615 | 19 | *ERCC1* | C/T | Exon | -- | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | 0.26724 | 0.989 |
| rs2298881 | 19 | *ERCC1* | A/C/T | Intron | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | 0.252611 | 0 |
| rs3212955 | 19 | *ERCC1* | A/G | Intron | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.246701 | 0 |
| rs3212961 | 19 | *ERCC1* | A/C/T | Intron | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0 |
| rs3212986 | 19 | *ERCC1* | A/C/G/T | Exon | Y | -- | -- | -- | -- | benign | -- | -- | -- | -- | -- | 0.305187 | 0 |
| rs735482 | 19 | *ERCC1* | A/C | Exon | Y | -- | -- | -- | -- | benign | -- | -- | -- | -- | -- | 0 | 0 |
| rs1052555 | 19 | *ERCC2* | C/T | Exon | -- | -- | Y | Y | -- | -- | -- | -- | -- | -- | -- | 0.478925 | 1 |
| rs13181 | 19 | *ERCC2* | A/G/T | Exon | Y | -- | Y | Y | -- | benign | -- | -- | -- | -- | -- | 0.585468 | 0.999 |
| rs238406 | 19 | *ERCC2* | G/T | Exon | -- | -- | Y | Y | -- | -- | -- | -- | -- | -- | -- | 0.36557 | 0.996 |
| rs238417 | 19 | *ERCC2* | A/C/G | Intron | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.037099 | 0 |
| rs50871 | 19 | *ERCC2* | G/T | Intron | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0.001 |
| rs50872 | 19 | *ERCC2* | A/C/T | Intron | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.137364 | 0.001 |
| rs4150441 | 2 | *ERCC3* | A/G | Intron | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0 |
| rs4150448 | 2 | *ERCC3* | A/G | Intron | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0 |
| rs4150506 | 2 | *ERCC3* | C/T | Intron | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | NA | 0 |
| rs1799801 | 16 | *ERCC4* | C/T | Exon | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.205381 | 0.326 |
| rs2276464 | 16 | *ERCC4* | A/C/G | 3'-UTR | -- | -- | -- | -- | -- | -- | -- | -- | -- | Y | Y | 0 | 0 |
| rs254942 | 16 | *ERCC4* | A/C/G/T | Intron | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.168034 | 0.005 |
| rs1047768 | 13 | *ERCC5* | C/T | Exon | -- | -- | Y | Y | -- | -- | -- | -- | -- | -- | -- | 0.24405 | 0.914 |
| rs2094258 | 13 | *ERCC5* | A/G | Promoter | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | 0 | 0.001 |
| rs2228959 | 13 | *ERCC5* | A/C | Exon | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.181402 | 0.509 |
| rs2296147 | 13 | *ERCC5* | C/T | Promoter | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | 0.175993 | 0 |
| rs4150291 | 13 | *ERCC5* | A/T | Intron | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0 |
| rs4150383 | 13 | *ERCC5* | A/G | Intron | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0 |
| rs751402 | 13 | *ERCC5* | C/T | Promoter | -- | -- | Y | Y | -- | -- | -- | -- | Y | -- | -- | 0.25613 | 0 |
| rs873601 | 13 | *ERCC5* | A/G | Exon | -- | -- | Y | Y | -- | -- | -- | -- | -- | Y | Y | 0 | 0.005 |
| rs10817938 | 9 | *XPA* | C/T | Promoter | -- | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | NA | 0.94 |
| rs2808668 | 9 | *XPA* | C/G/T | Intron | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0.004 |
| rs3176629 | 9 | *XPA* | C/T | Promoter | -- | -- | -- | -- | -- | -- | -- | -- | Y | -- | -- | 0 | 0 |
| rs1870134 | 3 | *XPC* | C/G/T | Exon | Y | -- | -- | Y | -- | -- | -- | -- | -- | -- | -- | 0.272801 | 0 |
| rs2228000 | 3 | *XPC* | C/T | Exon | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.136701 | 0 |
| rs2228001 | 3 | *XPC* | A/C | Exon | Y | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.189938 | 1 |
| rs2470352 | 3 | *XPC* | A/G/T | Exon | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0 |
| rs2607775 | 3 | *XPC* | C/G | Exon | -- | -- | -- | Y | -- | -- | -- | -- | Y | -- | -- | 0.282058 | 0 |

SNP: Single nucleotide polymorphism; nsSNP: Non-synonymous SNP; ESE: Exon splicing enhancer; ESS: Exon splicing silencer; TFBS: Transcription factor binding site.

**Table 2 Association between nucleotide excision repair polymorphisms and colorectal cancer risk in the validation stage1, *n* (%)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **SNP genotype** | **NCBI Ref** | **CRC** | **CON** | ***P-*value** | **OR (95%CI)** |
| DDB2 |  |  |  |  |  |
| rs2029298 |  | *n* = 849 | *n* = 849 |  |  |
| GG | 32 (37.2) | 393 (46.3) | 385 (45.3) |  | 1 (Ref) |
| GA | 38 (44.2) | 359 (42.3) | 368 (43.3) | 0.650 | 0.95 (0.78-1.17) |
| AA | 16 (18.6) | 97 (11.4) | 96 (11.3) | 0.919 | 0.98 (0.72-1.35) |
| GA + AA *vs* GG |  |  |  | 0.677 | 0.96 (0.79-1.16) |
| AA *vs* GA + GG |  |  |  | 0.980 | 1.00 (0.74-1.36) |
| *P*HWE | 0.584 |  | 0.570 |  |  |
| ERCC1 |  |  |  |  |  |
| rs11615 |  | *n* = 850 | *n* = 847 |  |  |
| CC | 54 (62.8) | 518 (60.9) | 494 (58.3) |  | 1 (Ref) |
| CT | 24 (27.9) | 293 (34.5) | 305 (36.0) | 0.355 | 0.91 (0.74-1.11) |
| TT | 8 (9.3) | 39 (4.6) | 48 (5.7) | 0.248 | 0.77 (0.50-1.20) |
| CT + TT *vs* CC |  |  |  | 0.244 | 0.89 (0.73-1.08) |
| TT *vs* CT + CC |  |  |  | 0.321 | 0.80 (0.52-1.24) |
| *P*HWE | 0.200 |  | 0.919 |  |  |
| rs735482 |  | *n* = 836 | *n* = 838 |  |  |
| CC | 18 (20.9) | 169 (20.2) | 168 (20.0) |  | 1 (Ref) |
| CA | 40 (46.5) | 405 (48.4) | 403 (48.1) | 0.966 | 1.00 (0.77-1.28) |
| AA | 28 (32.6) | 262 (31.3) | 267 (31.9) | 0.856 | 0.98 (0.74-1.28) |
| CA + AA *vs* CC |  |  |  | 0.920 | 0.99 (0.78-1.26) |
| AA *vs* CA + CC |  |  |  | 0.812 | 0.98 (0.79-1.20) |
| *P*HWE | 0.752 |  | 0.477 |  |  |
| ERCC2 |  |  |  |  |  |
| rs1052555 |  | *n* = 852 | *n* = 851 |  |  |
| CC | NA | 767 (90.0) | 759 (89.2) |  | 1 (Ref) |
| CT | NA | 84 (9.9) | 91 (10.7) | 0.605 | 0.92 (0.67-1.26) |
| TT | NA | 1 (0.1) | 1 (0.1) | 0.970 | 0.95 (0.06-15.21) |
| CT + TT *vs* CC |  |  |  | 0.602 | 0.92 (0.67-1.26) |
| TT *vs* CT + CC |  |  |  | 0.971 | 0.95 (0.06-15.22) |
| *P*HWE | NA |  | 0.307 |  |  |
| rs50871 |  | *n* = 838 | *n* = 845 |  |  |
| TT | 40 (46.5) | 429 (51.2) | 451 (53.4) |  | 1 (Ref) |
| TG | 36 (41.9) | 337 (40.2) | 358 (42.4) | 0.922 | 0.99 (0.81-1.21) |
| GG | 10 (11.6) | 72 (8.6) | 36 (4.3) | 0.001 | 2.09 (1.37-3.19) |
| TG + GG *vs* TT |  |  |  | 0.374 | 1.09 (0.90-1.32) |
| GG *vs* TG + TT |  |  |  | < 0.001 | 2.08 (1.38-3.15) |
| *P*HWE | 1.000 |  | 0.001 |  |  |
| ERCC5 |  |  |  |  |  |
| rs1047768 |  | *n* = 839 | *n* = 845 |  |  |
| CC | 8 (9.3) | 75 (8.9) | 71 (8.4) |  | 1 (Ref) |
| CT | 30 (34.9) | 348 (41.5) | 351 (41.5) | 0.735 | 0.94 (0.66-1.35) |
| TT | 48 (55.8) | 416 (49.6) | 423 (50.1) | 0.708 | 0.94 (0.66-1.33) |
| CT + TT *vs* CC |  |  |  | 0.717 | 0.94 (0.67-1.32) |
| TT *vs* CT + CC |  |  |  | 0.822 | 0.98 (0.81-1.19) |
| *P*HWE | 0.480 |  | 0.880 |  |  |
| rs2094258 |  | *n* = 843 | *n* = 841 |  |  |
| GG | 38 (44.2) | 307 (36.4) | 326 (38.8) |  | 1 (Ref) |
| GA | 42 (48.8) | 409 (48.5) | 392 (46.6) | 0.389 | 1.10 (0.89-1.35) |
| AA | 6 (7.0) | 127 (15.1) | 123 (14.6) | 0.615 | 1.08 (0.80-1.45) |
| GA + AA *vs* GG |  |  |  | 0.370 | 1.10 (0.90-1.33) |
| AA *vs* GA + GG |  |  |  | 0.837 | 1.03 (0.79-1.35) |
| *P*HWE | 0.403 |  | 0.770 |  |  |
| rs2228959 |  | *n* = 841 | *n* = 851 |  |  |
| CC | 74 (86.0) | 754 (89.7) | 782 (91.9) |  | 1 (Ref) |
| CA | 12 (14.0) | 83 (9.9) | 62 (7.3) | 0.051 | 1.41 (1.00-1.99) |
| AA | 0 (0.0) | 4 (0.5) | 7 (0.8) | 0.408 | 0.59 (0.17-2.04) |
| CA + AA *vs* CC |  |  |  | 0.095 | 1.33 (0.95-1.85) |
| AA *vs* CA + CC |  |  |  | 0.383 | 0.58 (0.17-1.98) |
| *P*HWE | 1.000 |  | < 0.001 |  |  |
| rs2296147 |  | *n* = 844 | *n* = 847 |  |  |
| TT | 52 (60.5) | 508 (60.2) | 517 (61.0) |  | 1 (Ref) |
| TC | 32 (37.2) | 294 (34.8) | 289 (34.1) | 0.684 | 1.04 (0.85-1.28) |
| CC | 2 (2.3) | 42 (5.0) | 41 (4.8) | 0.904 | 1.03 (0.66-1.61) |
| TC + CC *vs* TT |  |  |  | 0.679 | 1.04 (0.86-1.27) |
| CC *vs* TC + TT |  |  |  | 0.952 | 1.01 (0.65-1.58) |
| *P*HWE | 0.439 |  | 0.940 |  |  |
| rs873601 |  | *n* = 842 | *n* = 837 |  |  |
| GG | 16 (18.6) | 230 (27.3) | 223 (26.6) |  | 1 (Ref) |
| GA | 48 (55.8) | 435 (51.7) | 413 (49.3) | 0.807 | 1.03 (0.82-1.29) |
| AA | 22 (25.6) | 177 (21.0) | 201 (24.0) | 0.310 | 0.87 (0.66-1.14) |
| GA + AA *vs* GG |  |  |  | 0.849 | 0.98 (0.79-1.22) |
| AA *vs* GA + GG |  |  |  | 0.155 | 0.85 (0.67-1.07) |
| *P*HWE | 0.439 |  | 0.719 |  |  |
| XPA |  |  |  |  |  |
| rs10817938 |  | *n* = 823 | *n* = 822 |  |  |
| TT | 58 (67.4) | 511 (62.1) | 547 (66.5) |  | 1(Ref) |
| TC | 24 (27.9) | 259 (31.5) | 241 (29.3) | 0.231 | 1.14 (0.92-1.41) |
| CC | 4 (4.7) | 53 (6.4) | 34 (4.1) | 0.021 | 1.70 (1.08-2.66) |
| TC + CC *vs* TT |  |  |  | 0.071 | 1.21 (0.98-1.48) |
| CC *vs* TC + TT |  |  |  | 0.033 | 1.62 (1.04-2.52) |
| *P*HWE | 0.655 |  | 0.257 |  |  |
| rs3176629 |  | *n* = 847 | *n* = 852 |  |  |
| CC | 68 (79.1) | 689 (81.3) | 706 (82.9) |  | 1 (Ref) |
| CT | 18 (20.9) | 151 (17.8) | 133 (15.6) | 0.240 | 1.17 (0.90-1.51) |
| TT | 0 (0.0) | 7 (0.8) | 13 (1.5) | 0.225 | 0.56 (0.22-1.42) |
| CT + TT *vs* CC |  |  |  | 0.399 | 1.11 (0.87-1.43) |
| TT *vs* CT + CC |  |  |  | 0.205 | 0.55 (0.22-1.39) |
| *P*HWE | 0.752 |  | 0.024 |  |  |
| XPC |  |  |  |  |  |
| rs2607775 |  | *n* = 840 | *n* = 850 |  |  |
| CC | 76 (84.5) | 755 (89.9) | 792 (93.2) |  | 1(Ref) |
| CG | 12 (13.3) | 80 (9.5) | 56 (6.6) | 0.027 | 1.49 (1.05-2.13) |
| GG | 2 (2.2) | 5 (0.6) | 2 (0.2) | 0.219 | 2.81 (0.54-14.56) |
| CG + GG *vs* CC |  |  |  | 0.016 | 1.54 (1.09-2.18) |
| GG *vs* CG + CC |  |  |  | 0.238 | 2.69 (0.52-13.95) |
| *P*HWE | 0.251 |  | 0.343 |  |  |
| 1*P* was adjusted by gender and age. Statistically significant associations are in bold (*P* < 0.05). SNP: Single nucleotide polymorphism; NCBI Ref: Reference frequency of the SNPs in healthy controls (Beijing Han, China, NCBI database); CRC: Colorectal cancer; CON: Control; OR: Odds ratio; CI: Confidence interval; *P*HWE: Hardy-Weinberg Equilibrium in control group; NA: Not available. | | | | | |
|
|
|

**Table 3 Cumulative effect of nucleotide excision repair polymorphisms associated with colorectal cancer risk1, *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Number of SNP risk genotypes** | **CRC** | **CON** | ***P-*value** | **OR (95%CI)** |
|
|  | *n* = 841 | *n* = 847 |  |  |
| 0 | 706 (83.9) | 755 (89.1) |  | 1 (Ref) |
| 1 | 131 (15.6) | 92 (10.9) | 0.004 | 1.53 (1.15-2.04) |
| 2 | 4 (0.5) | 0 (0.0) | NA | NA |
|  |  |  | *P*trend = 0.001 | |
| 1*P* was adjusted by gender and age. Statistically significant associations are in bold (*P* < 0.05). SNP: Single nucleotide polymorphism; CRC: Colorectal cancer; CON: Control; OR: Odds ratio; CI: Confidence interval; NA: Not available. | | | | |
|

**Table 4 Effect of interaction between nucleotide excision repair polymorphisms and environmental factors on colorectal cancer risk1**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **SNP genotype** | **Smoking** | | **Drinking** | | ***Helicobacter pylori* infection** | |
| **No** | **Yes** | **No** | **Yes** | **Negative** | **Positive** |
| DDB2 | | | | | | |
| rs2029298 | *n* = 981 | *n* = 468 | *n* = 1190 | *n* = 257 | *n* = 810 | *n* = 443 |
| GA + AA | | | | | | |
| Case/Control | 312/220 | 142/104 | 367/274 | 87/49 | 164/286 | 189/44 |
| OR (95%CI) | 1 (Ref) | 0.96 (0.71-1.31) | 1 (Ref) | 1.33 (0.90-1.95) | 1 (Ref) | 7.49 (5.12-10.96) |
| GG | | | | | | |
| Case/Control | 267/182 | 124/98 | 330/219 | 61/60 | 140/220 | 158/52 |
| OR (95%CI) | 1.03 (0.80-1.34) | 0.89 (0.65-1.22) | 1.13 (0.89-1.42) | 0.76 (0.51-1.12) | 1.11 (0.83-1.48) | 5.30 (3.67-7.65) |
|  | *P*interaction = 0.618 | | *P*interaction = 0.019 OR (95%CI) = 0.52 (0.30-0.90) | | *P*interaction = 0.095 | |
| ERCC1 | | | | | | |
| rs11615 | *n* = 982 | *n* = 467 | *n* = 1190 | *n* = 257 | *n* = 812 | *n* = 444 |
| CT + TT | | | | | | |
| Case/Control | 231/160 | 101/88 | 278/205 | 54/40 | 110/210 | 146/42 |
| OR (95%CI) | 1 (Ref) | 0.80 (0.56-1.13) | 1 (Ref) | 1.00 (0.64-1.56) | 1 (Ref) | 6.64 (4.39-10.04) |
| CC | | | | | | |
| Case/Control | 349/242 | 165/113 | 421/286 | 93/70 | 194/298 | 203/53 |
| OR (95%CI) | 1.00 (0.77-1.30) | 1.01 (0.74-1.38) | 1.09 (0.86-1.37) | 0.98 (0.68-1.40) | 1.24 (0.93-1.67) | 7.31 (5.00-10.70) |
|  | *P*interaction = 0.309 | | *P*interaction = 0.749 | | *P*interaction = 0.642 | |
| rs735482 | *n* = 968 | *n* = 461 | *n* = 1171 | *n* = 256 | *n* = 803 | *n* = 434 |
| AA | | | | | | |
| Case/Control | 175/124 | 87/64 | 213/148 | 49/40 | 89/161 | 115/24 |
| OR (95%CI) | 1 (Ref) | 0.96 (0.65-1.43) | 1 (Ref) | 0.85 (0.53-1.36) | 1 (Ref) | 8.67 (5.20-14.44) |
| CA + CC | | | | | | |
| Case/Control | 396/273 | 174/136 | 471/339 | 99/68 | 212/341 | 224/71 |
| OR (95%CI) | 1.03(0.78-1.36) | 0.91(0.66-1.25) | 0.97(0.75-1.24) | 1.01(0.70-1.47) | 1.13 (0.82-1.53) | 5.71 (3.94-8.28) |
|  | *P*interaction = 0.638 | | *P*interaction = 0.446 | | *P*interaction = 0.082 | |
| ERCC2 | | | | | | |
| rs1052555 | *n* = 986 | *n* = 468 | *n* = 1193 | *n* = 259 | *n* = 811 | *n* = 447 |
| CT + TT | | | | | | |
| Case/Control | 55/39 | 30/27 | 68/56 | 17/10 | 27/54 | 39/11 |
| OR (95%CI) | 1 (Ref) | 0.79 (0.41-1.53) | 1 (Ref) | 1.40 (0.59-3.30) | 1 (Ref) | 7.09 (3.15-15.99) |
| CC | | | | | | |
| Case/Control | 527/365 | 236/175 | 632/437 | 131/101 | 277/453 | 312/85 |
| OR (95%CI) | 1.02 (0.67-1.58) | 0.96 (0.61-1.51) | 1.19 (0.82-1.73) | 1.07 (0.69-1.66) | 1.22 (0.75-1.99) | 7.34 (4.36-12.35) |
|  | *P*interaction = 0.624 | | *P*interaction = 0.319 | | *P*interaction = 0.712 | |
| ERCC5 | | | | | | |
| rs1047768 | *n* = 973 | *n* = 464 | *n* = 1177 | *n* = 258 | *n* = 808 | *n* = 437 |
| CT + TT | | | | | | |
| Case/Control | 524/368 | 236/190 | 622/452 | 138/103 | 272/460 | 317/88 |
| OR (95%CI) | 1 (Ref) | 0.87 (0.69-1.10) | 1 (Ref) | 0.97 (0.73-1.29) | 1 (Ref) | 6.09 (4.61-8.06) |
| CC | | | | | | |
| Case/Control | 49/32 | 26/12 | 66/37 | 9/8 | 29/47 | 26/6 |
| OR (95%CI) | 1.08 (0.68-1.71) | 1.52 (0.76-3.06) | 1.30 (0.85-1.97) | 0.82 (0.31-2.14) | 1.04 (0.64-1.70) | 7.33 (2.98-18.03) |
|  | *P*interaction = 0.241 | | *P*interaction = 0.491 | | *P*interaction = 0.843 | |
| rs2094258 | *n* = 973 | *n* = 464 | *n* = 1180 | *n* = 255 | *n* = 805 | *n* = 443 |
| GG | | | | | | |
| Case/Control | 209/150 | 97/70 | 251/180 | 55/40 | 119/203 | 116/38 |
| OR (95%CI) | 1 (Ref) | 1.00 (0.69-1.44) | 1 (Ref) | 0.99 (0.63-1.55) | 1 (Ref) | 5.21 (3.39-8.01) |
| GA + AA | | | | | | |
| Case/Control | 364/250 | 169/128 | 442/307 | 91/69 | 181/302 | 233/56 |
| OR (95%CI) | 1.05(0.80-1.36) | 0.95(0.69-1.29) | 1.03(0.81-1.31) | 0.95(0.66-1.37) | 1.02 (0.76-1.37) | 7.10 (4.91-10.27) |
|  | *P*interaction = 0.587 | | *P*interaction = 0.685 | | *P*interaction = 0.314 | |
| rs2296147 | *n* = 979 | *n* = 466 | *n* = 1185 | *n* = 258 | *n* = 807 | *n* = 440 |
| TT | | | | | | |
| Case/Control | 356/251 | 151/126 | 426/301 | 81/75 | 184/298 | 207/59 |
| OR (95%CI) | 1 (Ref) | 0.85 (0.64-1.13) | 1 (Ref) | 0.76 (0.54-1.08) | 1 (Ref) | 5.68 (4.03-8.01) |
| TC+CC | | | | | | |
| Case/Control | 221/151 | 112/77 | 268/190 | 65/37 | 118/207 | 138/36 |
| OR (95%CI) | 1.03(0.79-1.34) | 1.03(0.74-1.43) | 1.00(0.79-1.26) | 1.24(0.81-1.91) | 0.92 (0.69-1.24) | 6.21 (4.12-9.36) |
|  | *P*interaction = 0.506 | | *P*interaction = 0.089 | | *P*interaction = 0.562 | |
| rs873601 | *n* = 974 | *n* = 462 | *n* = 1179 | *n* = 255 | *n* = 798 | *n* = 439 |
| AA | | | | | | |
| Case/Control | 130/94 | 47/51 | 148/116 | 29/28 | 69/126 | 75/25 |
| OR (95%CI) | 1 (Ref) | 0.67 (0.41-1.07) | 1 (Ref) | 0.81 (0.46-1.44) | 1 (Ref) | 5.48 (3.19-9.40) |
| GA + GG | | | | | | |
| Case/Control | 446/304 | 215/149 | 543/372 | 118/80 | 234/369 | 269/70 |
| OR (95%CI) | 1.06 (0.78-1.44) | 1.04 (0.74-1.46) | 1.14 (0.87-1.51) | 1.16 (0.80-1.68) | 1.16 (0.83-1.62) | 7.02 (4.73-10.41) |
|  | *P*interaction = 0.202 | | *P*interaction = 0.550 | | *P*interaction = 0.764 | |
| XPA | | | | | | |
| rs10817938 | *n* = 952 | *n* = 453 | *n* = 1152 | *n* = 252 | *n* = 785 | *n* = 429 |
| TC + TT | | | | | | |
| Case/Control | 527/380 | 239/183 | 631/459 | 135/103 | 281/470 | 311/88 |
| OR (95%CI) | 1 (Ref) | 0.94 (0.75-1.19) | 1 (Ref) | 0.95 (0.72-1.27) | 1 (Ref) | 5.91 (4.47-7.81) |
| CC | | | | | | |
| Case/Control | 33/12 | 20/11 | 45/17 | 8/6 | 14/20 | 25/5 |
| OR (95%CI) | 1.98 (1.01-3.89) | 1.31 (0.62-2.77) | 1.93 (1.09-3.41) | 0.97 (0.33-2.81) | 1.17 (0.58-2.36) | 8.36 (3.17-22.09) |
|  | *P*interaction = 0.516 | | *P*interaction = 0.299 | | *P*interaction = 0.738 | |
| XPC | | | | | | |
| rs2607775 | *n* = 979 | *n* = 463 | *n* = 1184 | *n* = 256 | *n* = 809 | *n* = 439 |
| CC | | | | | | |
| Case/Control | 513/369 | 238/195 | 617/458 | 134/103 | 273/475 | 314/88 |
| OR (95%CI) | 1 (Ref) | 0.88 (0.70-1.11) | 1 (Ref) | 0.97 (0.73-1.28) | 1 (Ref) | 6.21 (4.70-8.21) |
| CG + GG | | | | | | |
| Case/Control | 61/36 | 24/6 | 73/36 | 12/7 | 28/33 | 30/7 |
| OR (95%CI) | 1.22 (0.79-1.88) | 2.88 (1.16-7.11) | 1.51 (0.99-2.28) | 1.27 (0.50-3.26) | 1.48 (0.87-2.50) | 7.46 (3.23-17.21) |
|  | *P*interaction=0.066 | | *P*interaction=0.728 | | *P*interaction=0.766 | |

1*P* for interaction was adjusted by gender and age. Statistically significant associations are in bold (*P* < 0.05). SNP: Single nucleotide polymorphism; CRC: Colorectal cancer; CON: Control; OR: Odds ratio; CI: Confidence interval.

**Table 5 Association between host factors and the overall survival of colorectal cancer patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Factor** | **CRC patients** | **Death** | **MST (M)** | ***P*-value** |
| Total | *n* = 565 | *n* = 95 |  |  |
| Gender |  |  |  | 0.862 |
| Male | 384 | 63 | 46.61 |  |
| Female | 181 | 32 | 47.11 |  |
| Age (yr) |  |  |  | 0.127 |
| ≤60 | 322 | 46 | 47.91 |  |
| >60 | 243 | 49 | 44.71 |  |
| Smoking |  |  |  | 0.111 |
| Ever Smoker | 180 | 23 | 48.71 |  |
| Never Smoker | 383 | 72 | 45.91 |  |
| Drinking |  |  |  | 0.157 |
| Drinker | 107 | 14 | 49.31 |  |
| Non-drinker | 456 | 81 | 46.11 |  |
| TNM stage |  |  |  | <0.001 |
| Ⅰ + Ⅱ | 336 | 23 | 52.11 |  |
| Ⅲ + Ⅳ | 223 | 69 | 48 |  |
| Macroscopic type |  |  |  | <0.001 |
| Protrude type | 104 | 5 | 53.41 |  |
| Ulcerative/Invasive type | 458 | 90 | 45.21 |  |
| Histological type |  |  |  | <0.001 |
| High/Middle differentiation | 367 | 40 | 50.21 |  |
| Low differentiation | 196 | 55 | 39.31 |  |
| Depth of invasion |  |  |  | <0.001 |
| T1 + T2 | 114 | 6 | 53.41 |  |
| T3 + T4 | 450 | 89 | 44.91 |  |
| Growth mode |  |  |  | <0.001 |
| Nest | 236 | 18 | 52.11 |  |
| Invasion | 326 | 77 | 42.61 |  |
| Lymphatic metastasis |  |  |  | < 0.001 |
| Positive | 217 | 68 | 47 |  |
| Negative | 342 | 24 | 52.01 |  |

CRC: Colorectal cancer; MST (M): Median survival time (mo). 1Mean survival time was provided when MST could not be calculated. Statistically significant associations are in bold (*P* < 0.05).

**Table 6 Association between nucleotide excision repair polymorphisms and colorectal cancer prognosis**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **SNP genotype** | **CRC patients** | **Death** | **MST (M)** | **Univariate** | | **Multivariate** | |
| ***P-*value** | **HR (95%CI)** | ***P*-value** | **HR (95%CI)** |
| DDB2 |  |  |  |  |  |  |  |
| rs2029298 | *n* = 560 | *n* = 94 |  |  |  |  |  |
| GG | 262 | 50 | 44.41 |  | 1(Ref) |  | 1 (Ref) |
| GA | 230 | 35 | 47.41 | 0.368 | 0.82 (0.53-1.26) | 0.393 | 0.82 (0.53-1.29) |
| AA | 68 | 9 | 48.61 | 0.265 | 0.67 (0.33-1.36) | 0.467 | 0.77 (0.37-1.57) |
| GA + AA *vs* GG |  |  |  | 0.235 | 0.78 (0.52-1.17) | 0.307 | 0.81 (0.53-1.22) |
| AA *vs* GA + GG |  |  |  | 0.370 | 0.73 (0.37-1.45) | 0.581 | 0.82 (0.41-1.65) |
| ERCC1 |  |  |  |  |  |  |  |
| rs11615 | *n* = 561 | *n* = 95 |  |  |  |  |  |
| CC | 345 | 62 | 46.41 |  | 1 (Ref) |  | 1 (Ref) |
| CT | 188 | 29 | 47.21 | 0.647 | 0.90 (0.58-1.40) | 0.947 | 1.02 (0.65-1.59) |
| TT | 28 | 4 | 45.81 | 0.955 | 0.97 (0.35-2.67) | 0.975 | 0.98 (0.35-2.76) |
| CT + TT *vs* CC |  |  |  | 0.662 | 0.91 (0.60-1.39) | 0.974 | 0.99 (0.65-1.53) |
| TT *vs* CT + CC |  |  |  | 0.999 | 1.00 (0.37-2.73) | 0.911 | 0.94 (0.34-2.60) |
| rs735482 | *n* = 552 | *n* = 91 |  |  |  |  |  |
| CC | 123 | 23 | 46.81 |  | 1 (Ref) |  | 1 (Ref) |
| CA | 258 | 38 | 47.31 | 0.982 | 0.99 (0.59-1.67) | 0.582 | 1.16 (0.69-1.96) |
| AA | 171 | 30 | 45.51 | 0.603 | 1.16 (0.67-1.99) | 0.774 | 0.92 (0.53-1.61) |
| CA + AA *vs* CC |  |  |  | 0.829 | 1.05 (0.66-1.69) | 0.923 | 1.02 (0.64-1.65) |
| AA *vs* CA + CC |  |  |  | 0.517 | 1.16 (0.75-1.79) | 0.521 | 0.86 (0.55-1.35) |
| ERCC2 |  |  |  |  |  |  |  |
| rs1052555 | *n* = 563 | *n* = 95 |  |  |  |  |  |
| CC | 506 | 86 | 46.61 |  | 1 (Ref) |  | 1 (Ref) |
| CT | 56 | 8 | 48.31 | 0.377 | 0.72 (0.35-1.49) | 0.998 | 1.00 (0.48-2.09) |
| TT | 1 | 1 | 2 | <0.001 | 49.73 (6.37-388.47) | 0.010 | 14.99 (1.90-118.10) |
| CT + TT *vs* CC |  |  |  | 0.551 | 0.81 (0.41-1.61) | 0.744 | 1.12 (0.56-2.26) |
| TT *vs* CT + CC |  |  |  | <0.001 | 55.22 (7.07-431.35) | 0.009 | 15.89 (2.02-125.16) |
| rs50871 | *n* = 551 | *n* = 92 |  |  |  |  |  |
| TT | 294 | 43 | 47.01 |  | 1 (Ref) |  | 1 (Ref) |
| TG | 210 | 40 | 45.71 | 0.256 | 1.28 (0.83-1.98) | 0.446 | 1.19 (0.77-1.84) |
| GG | 47 | 9 | 45.81 | 0.541 | 1.25 (0.61-2.57) | 0.576 | 0.80 (0.37-1.74) |
| TG + GG *vs* TT |  |  |  | 0.239 | 1.28 (0.85-1.93) | 0.646 | 1.10 (0.73-1.68) |
| GG *vs* TG + TT |  |  |  | 0.749 | 1.12 (0.56-2.23) | 0.354 | 0.71 (0.34-1.47) |
| ERCC5 |  |  |  |  |  |  |  |
| rs1047768 | *n* = 553 | *n* = 92 |  |  |  |  |  |
| CC | 55 | 9 | 46.71 |  | 1 (Ref) |  | 1 (Ref) |
| CT | 233 | 44 | 46.51 | 0.785 | 1.11 (0.54-2.26) | 0.945 | 0.97 (0.45-2.09) |
| TT | 265 | 39 | 47.01 | 0.933 | 1.03 (0.50-2.13) | 0.542 | 0.78 (0.36-1.72) |
| CT + TT *vs* CC |  |  |  | 0.851 | 1.07 (0.54-2.13) | 0.768 | 0.90 (0.43-1.87) |
| TT *vs* CT + CC |  |  |  | 0.799 | 0.95 (0.63-1.43) | 0.387 | 0.83 (0.54-1.27) |
| rs2094258 | *n* = 555 | *n* = 93 |  |  |  |  |  |
| GG | 207 | 38 | 46.61 |  | 1 (Ref) |  | 1 (Ref) |
| GA | 269 | 42 | 47.01 | 0.721 | 0.92 (0.60-1.43) | 0.400 | 0.82 (0.53-1.29) |
| AA | 79 | 13 | 44.31 | 0.973 | 0.99 (0.53-1.86) | 0.588 | 0.84 (0.44-1.59) |
| GA + AA *vs* GG |  |  |  | 0.773 | 0.94 (0.62-1.42) | 0.424 | 0.84 (0.55-1.29) |
| AA *vs* GA + GG |  |  |  | 0.869 | 1.05 (0.59-1.89) | 0.916 | 1.03 (0.57-1.87) |
| rs2228959 | *n* = 558 | *n* = 93 |  |  |  |  |  |
| CC | 501 | 82 | 47.11 |  | 1 (Ref) |  | 1 (Ref) |
| CA | 53 | 9 | 45.41 | 0.768 | 1.11 (0.56-2.21) | 0.811 | 0.92 (0.46-1.85) |
| AA | 4 | 2 | 13.81 | 0.006 | 7.18 (1.75-29.50) | 0.046 | 4.32 (1.03-18.17) |
| CA + AA *vs* CC |  |  |  | 0.402 | 1.31 (0.70-2.46) | 0.847 | 1.07 (0.56-2.02) |
| AA *vs* CA + CC |  |  |  | 0.006 | 7.16 (1.75-29.32) | 0.049 | 4.20 (1.00-17.60) |
| rs2296147 | *n* = 556 | *n* = 92 |  |  |  |  |  |
| TT | 318 | 46 | 47.41 |  | 1 (Ref) |  | 1 (Ref) |
| TC | 207 | 42 | 45.41 | 0.384 | 1.21(0.79-1.83) | 0.194 | 1.32(0.87-2.02) |
| CC | 31 | 4 | 48.11 | 0.691 | 0.81(0.29-2.26) | 0.658 | 1.32(0.38-4.57) |
| TC + CC *vs* TT |  |  |  | 0.484 | 1.16(0.77-1.74) | 0.184 | 1.33(0.87-2.02) |
| CC *vs* TC + TT |  |  |  | 0.573 | 0.75(0.28-2.04) | 0.978 | 1.02(0.31-3.32) |
| rs873601 | *n* = 558 | *n* = 95 |  |  |  |  |  |
| GG | 140 | 21 | 47.51 |  | 1 (Ref) |  | 1 (Ref) |
| GA | 301 | 49 | 46.91 | 0.745 | 1.09 (0.65-1.82) | 0.923 | 0.98 (0.58-1.64) |
| AA | 117 | 25 | 44.51 | 0.293 | 1.37 (0.76-2.44) | 0.713 | 1.12 (0.62-2.03) |
| GA + AA *vs* GG |  |  |  | 0.526 | 1.17 (0.72-1.90) | 0.951 | 1.02 (0.62-1.66) |
| AA *vs* GA + GG |  |  |  | 0.275 | 1.29 (0.82-2.04) | 0.473 | 1.19 (0.74-1.90) |
| XPA |  |  |  |  |  |  |  |
| rs10817938 | *n* = 545 | *n* = 93 |  |  |  |  |  |
| TT | 351 | 61 | 46.61 |  | 1 (Ref) |  | 1 (Ref) |
| TC | 163 | 29 | 46.21 | 0.815 | 1.05 (0.68-1.64) | 0.472 | 1.18 (0.75-1.88) |
| CC | 31 | 3 | 49.51 | 0.429 | 0.63 (0.20-2.00) | 0.903 | 0.93 (0.29-3.02) |
| TC + CC *vs* TT |  |  |  | 0.968 | 0.99 (0.65-1.52) | 0.489 | 1.17 (0.75-1.83) |
| CC *vs* TC+TT |  |  |  | 0.414 | 0.62 (0.20-1.96) | 0.863 | 0.90 (0.28-2.89) |
| rs3176629 | *n* = 558 | *n* = 94 |  |  |  |  |  |
| CC | 450 | 74 | 47.01 |  | 1 (Ref) |  | 1 (Ref) |
| CT | 103 | 19 | 44.81 | 0.470 | 1.20 (0.73-1.99) | 0.420 | 0.81 (0.48-1.36) |
| TT | 5 | 1 | 49.31 | 0.824 | 0.80 (0.11-5.76) | 0.660 | 0.64 (0.09-4.64) |
| CT + TT *vs* CC |  |  |  | 0.521 | 1.18 (0.72-1.93) | 0.375 | 0.79 (0.47-1.33) |
| TT *vs* CT + CC |  |  |  | 0.787 | 0.76 (0.11-5.47) | 0.690 | 0.67 (0.09-4.82) |
| XPC |  |  |  |  |  |  |  |
| rs2607775 | *n* = 556 | *n* = 92 |  |  |  |  |  |
| CC | 494 | 84 | 46.81 |  | 1 (Ref) |  | 1 (Ref) |
| CG | 57 | 8 | 46.31 | 0.739 | 0.88 (0.43-1.83) | 0.842 | 0.93 (0.44-1.94) |
| GG | 5 | 0 | NA | 0.525 | NA | 0.969 | NA |
| CG + GG *vs* CC |  |  |  | 0.555 | 0.80 (0.39-1.66) | 0.604 | 0.82 (0.40-1.72) |
| GG *vs* CG + CC |  |  |  | 0.528 | NA | 0.970 | NA |

SNP: Single nucleotide polymorphism; CRC: Colorectal cancer; MST (M): Median survival time (mo); HR: Hazard ratio; CI: Confidence interval; NA: Not available. 1mean survival time was provided when MST could not be calculated. Statistically significant associations are in bold (*P* < 0.05).